Bone Biologics Corporation, a developer of orthobiologic products for spine fusion markets, has announced the filing of a patent application with the United States Patent and Trademark Office (USPTO) for its novel NELL-1 protein.

The patent application is directed to compositions of rhNELL-1 polypeptide and uses thereof for treating bone conditions.

“This patent application marks a major milestone in our mission to bring effective treatments to spine fusion patients,” said Jeffrey Frelick, Chief Executive Officer of Bone Biologics.

The patent application, if approved, will strengthen Bone Biologics’ intellectual property portfolio and support the Company’s strategic plan to advance the clinical development program.

The company is undertaking work with select strategic partners that builds on the preclinical research of the NELL-1 protein. Bone Biologics is focusing development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications.